Compare Quest Diagnostics Inc (DGX) vs Eni SpA (E) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Eni SpA — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.06B), while Eni SpA trades at $55.45 (market cap $78.10B). The key difference: Eni SpA is far larger — about 3.1× Quest Diagnostics Inc's market cap, and Eni SpA pays the higher dividend (4.52%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Eni SpA for 53 Days on average.
| DGX | E | |
|---|---|---|
Market Cap | $25.06B | $78.10B |
Volume | 927,361 | 296,516 |
Sector | Health | Energy |
52-Week High | $247.45 | $57.61 |
52-Week Low | $173.49 | $34.03 |
Typical Hold Time | 56 Days | 53 Days |
Enterprise Value | $30.82B | $102.75B |
Dividend Yield | 1.52% | 4.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.03% with consistent earnings beats in recent quarters. The stock shows bearish technical signals despite strong fundamentals including 9.19% net margins and 14.35% ROE. Recent developments include a partnership with Apple Health app and concerns about Medicare reimbursement cuts affecting future revenue streams.
The outlook remains cautiously optimistic with a $250 consensus price target representing 8.3% upside potential. Key opportunities include growth in advanced diagnostics and consumer testing demand, while risks center on Medicare payment reductions and competitive pressures in the diagnostic services market.
Eni (E) trades at $55.62, up 1.96% today, amid a bearish technical signal. Revenue has declined from $132.5B in 2022 to $82.15B in 2025, though net income margin improved to 5.97% in 2026. The company maintains solid cash flow and a low P/E of 12.53. Recent news highlights expansion in humanoid robotics, LNG projects in Argentina, and fuel discounts in Italy, indicating strategic diversification and customer support initiatives.
The outlook is mixed; valuation appears attractive with low multiples, and analyst consensus leans hold (61.53%). However, declining revenue, recent earnings misses, and bearish technicals pose near-term risks. Upside depends on execution of new projects and stabilization of energy markets, while volatility in oil prices remains a key sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →
